Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.

Suppr

超能文献

作者信息

Jørgensen Heather G, Copland Mhairi, Holyoake Tessa L

出版信息

Cancer. 2005 Jan 1;103(1):210-11. doi: 10.1002/cncr.20742.

DOI:10.1002/cncr.20742

PMID:15540243

Abstract

摘要

相似文献

Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.

Cancer. 2005 Jan 1;103(1):210-11. doi: 10.1002/cncr.20742.

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.粒细胞集落刺激因子（非格司亭）可能会克服伊马替尼引起的慢性期慢性粒细胞白血病患者的中性粒细胞减少。

Cancer. 2004 Jun 15;100(12):2592-7. doi: 10.1002/cncr.20285.

G-CSF for imatinib-induced neutropenia.

Leukemia. 2003 Apr;17(4):805-7. doi: 10.1038/sj.leu.2402869.

Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.在慢性髓性白血病急变期患者中，伊马替尼相关的中性粒细胞减少可能无法通过非格司亭治疗得到缓解。

Clin Lab Haematol. 2006 Jun;28(3):208-10. doi: 10.1111/j.1365-2257.2006.00772.x.

Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.甲磺酸伊马替尼联合粒细胞集落刺激因子对晚期慢性髓性白血病患者白血病原始细胞的影响。

Acta Haematol. 2006;116(1):8-18. doi: 10.1159/000092342.

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.

Haematologica. 2003 Feb;88(2):227-9.

Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.伊马替尼诱导完全分子缓解后动员慢性髓性白血病患儿的Ph染色体阴性外周血干细胞

Pediatr Blood Cancer. 2008 Mar;50(3):639-41. doi: 10.1002/pbc.21017.

[Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].

Rinsho Ketsueki. 2004 Oct;45(10):1105-10.

Safety and efficacy of stem cell mobilization under imatinib therapy.伊马替尼治疗下干细胞动员的安全性和有效性。

Haematologica. 2003 Oct;88(10):1199-200.

Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.化疗后预防性使用粒细胞集落刺激因子不影响急性髓系白血病的生存率：一项荟萃分析。

Acta Haematol. 2009;121(4):223-6. doi: 10.1159/000225909. Epub 2009 Jun 19.

引用本文的文献

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.欧洲白血病网关于慢性髓性白血病治疗管理及不良事件避免的建议

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28.

Hematologic toxicities of small molecule tyrosine kinase inhibitors.小分子酪氨酸激酶抑制剂的血液学毒性。

Target Oncol. 2011 Dec;6(4):203-15. doi: 10.1007/s11523-011-0202-9. Epub 2011 Nov 30.

Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia.小檗胺克服伊马替尼诱导的中性粒细胞减少症，并使中国慢性期慢性髓性白血病患者获得细胞遗传学反应。

Int J Hematol. 2011 Aug;94(2):156-162. doi: 10.1007/s12185-011-0887-7. Epub 2011 Jul 5.

Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib.伊马替尼联合粒细胞集落刺激因子用于在接受伊马替尼治疗期间已获得部分或完全细胞遗传学缓解的慢性髓性白血病患者。

Case Rep Oncol. 2011 Apr 2;4(1):192-7. doi: 10.1159/000327512.

New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.造血干细胞与慢性粒细胞白血病的新实验及理论研究

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):88-97. doi: 10.1016/j.bcmd.2009.03.003. Epub 2009 May 2.

Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.慢性髓性白血病的发病机制、治疗效果及耐药动态——来自数学模型分析的见解

J Mol Med (Berl). 2008 Jan;86(1):17-27. doi: 10.1007/s00109-007-0241-y. Epub 2007 Jul 28.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验